How Twist Bioscience Synthesizes 32 Million DNA Sequences a Day for AI Drug Discovery

Episode 80

0:00-46:02

AI can design a molecule in seconds, however someone still has to build it and test it before it means anything. You're pouring resources into AI-driven molecule design, but nobody on your team has answered the harder question: can you actually make what the model just designed? Patrick Finn is President and Chief Operating Officer of Twist Bioscience, a company writing DNA on silicon chips at a scale of roughly 32 million distinct oligonucleotides a day. Under his leadership, Twist has become the manufacturing layer behind antibody discovery, liquid biopsy, and molecular residual disease testing programs across biotech. You'll get a clear picture of what happens after an AI model produces a candidate molecule, and why the synthesis step decides whether that design ever becomes usable data. Paddy breaks down how pooled DNA synthesis and display selection turn hundreds of thousands of candidates into model feedback in weeks instead of months, and where the manufacturability gap bites hardest as AI pushes sequences into territory nature never explored. This episode covers high-throughput DNA synthesis, target enrichment for liquid biopsy, tumor-informed molecular residual disease testing, and the economics of scaling antibody discovery.

Publisher

Data in Biotech

Link

www.corrdyn.com/

Published

October 14, 2026

Duration

46 min

Format

Podcast

Category

Issues · Science

Source

RSS feed

Host

CorrDyn

DI

Data in Biotech

@datainbiotech

#twistbiosciencesynthesizes #milliondnasequences #aidrugdiscovery #lifesciences

The Nile